Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 17 | 2023 | 173 | 5.660 |
Why?
|
| Chromatography, High Pressure Liquid | 15 | 2023 | 406 | 2.620 |
Why?
|
| Ovarian Neoplasms | 13 | 2015 | 303 | 1.760 |
Why?
|
| Chromatography, Liquid | 11 | 2023 | 140 | 1.680 |
Why?
|
| Rats | 25 | 2023 | 3261 | 1.410 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2021 | 638 | 1.280 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2021 | 1534 | 1.260 |
Why?
|
| Nicotinic Acids | 3 | 2013 | 11 | 1.070 |
Why?
|
| Reproducibility of Results | 13 | 2023 | 901 | 1.060 |
Why?
|
| Animals | 32 | 2023 | 14307 | 1.000 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2015 | 528 | 0.990 |
Why?
|
| Solvents | 2 | 2015 | 93 | 0.990 |
Why?
|
| Biological Availability | 6 | 2021 | 84 | 0.910 |
Why?
|
| Pyridazines | 2 | 2013 | 14 | 0.850 |
Why?
|
| Microsomes, Liver | 1 | 2022 | 69 | 0.850 |
Why?
|
| Propolis | 1 | 2021 | 3 | 0.830 |
Why?
|
| Weightlessness | 1 | 2021 | 14 | 0.790 |
Why?
|
| Flavonoids | 1 | 2021 | 78 | 0.790 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2015 | 40 | 0.770 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 59 | 0.750 |
Why?
|
| Stilbenes | 2 | 2021 | 41 | 0.720 |
Why?
|
| Mannose | 3 | 2017 | 25 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 355 | 0.620 |
Why?
|
| Serum | 1 | 2016 | 13 | 0.600 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 756 | 0.580 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2013 | 55 | 0.550 |
Why?
|
| Proline | 2 | 2015 | 37 | 0.540 |
Why?
|
| Solubility | 4 | 2021 | 115 | 0.530 |
Why?
|
| Indoles | 1 | 2016 | 154 | 0.530 |
Why?
|
| Glucuronides | 3 | 2023 | 10 | 0.510 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 107 | 0.480 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 6 | 0.480 |
Why?
|
| Drug Stability | 5 | 2018 | 110 | 0.480 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 44 | 0.470 |
Why?
|
| Administration, Oral | 3 | 2021 | 212 | 0.470 |
Why?
|
| Blood Coagulation | 1 | 2013 | 22 | 0.460 |
Why?
|
| Male | 21 | 2021 | 18870 | 0.460 |
Why?
|
| Ovary | 1 | 2013 | 101 | 0.460 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 124 | 0.450 |
Why?
|
| Curcumin | 1 | 2013 | 66 | 0.450 |
Why?
|
| Warfarin | 1 | 2013 | 59 | 0.440 |
Why?
|
| Anticoagulants | 1 | 2013 | 97 | 0.430 |
Why?
|
| Antipyrine | 1 | 2012 | 3 | 0.430 |
Why?
|
| Hindlimb Suspension | 1 | 2012 | 9 | 0.430 |
Why?
|
| Mycophenolic Acid | 2 | 2023 | 7 | 0.420 |
Why?
|
| Menthol | 1 | 2012 | 21 | 0.420 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 45 | 0.420 |
Why?
|
| Microsomes | 2 | 2022 | 52 | 0.410 |
Why?
|
| Neoplasms | 2 | 2022 | 1033 | 0.410 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 112 | 0.390 |
Why?
|
| Humans | 30 | 2022 | 34853 | 0.380 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2015 | 65 | 0.380 |
Why?
|
| Methylcellulose | 1 | 2009 | 6 | 0.360 |
Why?
|
| Isoxazoles | 1 | 2009 | 11 | 0.360 |
Why?
|
| Half-Life | 3 | 2015 | 52 | 0.360 |
Why?
|
| Nanoparticles | 3 | 2022 | 294 | 0.360 |
Why?
|
| Sucrose | 1 | 2009 | 27 | 0.350 |
Why?
|
| Nicotine | 1 | 2012 | 238 | 0.350 |
Why?
|
| Anticonvulsants | 1 | 2009 | 34 | 0.350 |
Why?
|
| Drug Compounding | 1 | 2009 | 70 | 0.350 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 25 | 0.330 |
Why?
|
| Delayed-Action Preparations | 2 | 2013 | 57 | 0.320 |
Why?
|
| Vitamin A | 1 | 2008 | 87 | 0.320 |
Why?
|
| Female | 24 | 2021 | 19873 | 0.310 |
Why?
|
| Genetic Variation | 3 | 2015 | 328 | 0.310 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 63 | 0.310 |
Why?
|
| Vitamins | 1 | 2008 | 91 | 0.300 |
Why?
|
| Risk | 5 | 2015 | 256 | 0.300 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 6 | 0.300 |
Why?
|
| Genome-Wide Association Study | 4 | 2015 | 271 | 0.300 |
Why?
|
| Niacin | 1 | 2006 | 23 | 0.290 |
Why?
|
| MicroRNAs | 1 | 2010 | 386 | 0.270 |
Why?
|
| Linear Models | 4 | 2021 | 253 | 0.270 |
Why?
|
| Plasma | 2 | 2022 | 29 | 0.260 |
Why?
|
| Nanospheres | 2 | 2014 | 7 | 0.250 |
Why?
|
| Alleles | 3 | 2021 | 284 | 0.240 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 555 | 0.240 |
Why?
|
| Mice | 8 | 2023 | 5668 | 0.240 |
Why?
|
| Hydrogen Sulfide | 1 | 2023 | 38 | 0.230 |
Why?
|
| Biological Transport | 2 | 2021 | 175 | 0.220 |
Why?
|
| Middle Aged | 9 | 2017 | 9642 | 0.220 |
Why?
|
| Genotype | 6 | 2015 | 641 | 0.220 |
Why?
|
| Glucuronidase | 1 | 2022 | 14 | 0.220 |
Why?
|
| Odds Ratio | 4 | 2015 | 517 | 0.220 |
Why?
|
| Time Factors | 3 | 2012 | 1681 | 0.210 |
Why?
|
| Glucosides | 1 | 2021 | 15 | 0.210 |
Why?
|
| Nitriles | 2 | 2013 | 66 | 0.210 |
Why?
|
| Fenoldopam | 1 | 2021 | 1 | 0.210 |
Why?
|
| Honey | 1 | 2021 | 11 | 0.210 |
Why?
|
| Magnesium Hydroxide | 1 | 2021 | 1 | 0.200 |
Why?
|
| Antacids | 1 | 2021 | 2 | 0.200 |
Why?
|
| Bismuth | 1 | 2021 | 3 | 0.200 |
Why?
|
| Antidiarrheals | 1 | 2021 | 3 | 0.200 |
Why?
|
| Aluminum Hydroxide | 1 | 2021 | 7 | 0.200 |
Why?
|
| Case-Control Studies | 6 | 2017 | 1056 | 0.200 |
Why?
|
| Salicylates | 1 | 2021 | 7 | 0.200 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 22 | 0.200 |
Why?
|
| Weightlessness Simulation | 1 | 2021 | 15 | 0.200 |
Why?
|
| Pyrimidines | 2 | 2013 | 112 | 0.200 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 102 | 0.200 |
Why?
|
| Drug Combinations | 1 | 2021 | 89 | 0.200 |
Why?
|
| Aged | 7 | 2017 | 6448 | 0.190 |
Why?
|
| Risk Factors | 6 | 2015 | 3414 | 0.190 |
Why?
|
| Aminopyridines | 1 | 2020 | 13 | 0.190 |
Why?
|
| Gene Frequency | 1 | 2021 | 155 | 0.190 |
Why?
|
| Drug Interactions | 1 | 2021 | 137 | 0.190 |
Why?
|
| Organometallic Compounds | 1 | 2021 | 68 | 0.190 |
Why?
|
| Oxyquinoline | 1 | 2020 | 5 | 0.190 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2021 | 82 | 0.190 |
Why?
|
| Tongue | 1 | 2019 | 11 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2020 | 42 | 0.180 |
Why?
|
| Tissue Distribution | 4 | 2023 | 197 | 0.180 |
Why?
|
| Pharmaceutical Solutions | 2 | 2015 | 5 | 0.170 |
Why?
|
| Chloroquinolinols | 1 | 2018 | 3 | 0.170 |
Why?
|
| Quantitative Trait Loci | 2 | 2015 | 68 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 396 | 0.160 |
Why?
|
| Protein Binding | 3 | 2015 | 913 | 0.160 |
Why?
|
| Temperature | 2 | 2009 | 275 | 0.150 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 80 | 0.150 |
Why?
|
| Rats, Inbred F344 | 3 | 2021 | 228 | 0.150 |
Why?
|
| Colonic Polyps | 1 | 2017 | 67 | 0.140 |
Why?
|
| Adenoma | 1 | 2017 | 89 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2014 | 91 | 0.140 |
Why?
|
| Copper Radioisotopes | 1 | 2015 | 8 | 0.140 |
Why?
|
| Adult | 7 | 2017 | 11034 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 33 | 0.130 |
Why?
|
| Phototherapy | 1 | 2015 | 19 | 0.130 |
Why?
|
| Veratrum Alkaloids | 1 | 2015 | 2 | 0.130 |
Why?
|
| Lutetium | 1 | 2015 | 3 | 0.130 |
Why?
|
| Radioisotopes | 1 | 2015 | 15 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 86 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2015 | 65 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 55 | 0.130 |
Why?
|
| Gonadotropins | 1 | 2014 | 21 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 44 | 0.130 |
Why?
|
| Anilides | 1 | 2014 | 27 | 0.130 |
Why?
|
| Species Specificity | 1 | 2015 | 233 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 79 | 0.130 |
Why?
|
| Liver | 2 | 2021 | 447 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 37 | 0.130 |
Why?
|
| Cyclohexanes | 1 | 2014 | 29 | 0.130 |
Why?
|
| Bilirubin | 1 | 2014 | 17 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 47 | 0.130 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 70 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 342 | 0.120 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2128 | 0.120 |
Why?
|
| Endometriosis | 1 | 2015 | 69 | 0.120 |
Why?
|
| Itraconazole | 1 | 2013 | 12 | 0.120 |
Why?
|
| Polysorbates | 1 | 2013 | 10 | 0.120 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 20 | 0.120 |
Why?
|
| Antibodies | 1 | 2014 | 135 | 0.120 |
Why?
|
| Polyglycolic Acid | 1 | 2013 | 35 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 34 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2014 | 1349 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 203 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 73 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 106 | 0.120 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2013 | 2 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2015 | 287 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2013 | 87 | 0.110 |
Why?
|
| Acetaminophen | 1 | 2013 | 24 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 781 | 0.110 |
Why?
|
| Biotransformation | 1 | 2013 | 65 | 0.110 |
Why?
|
| Hydrolysis | 1 | 2013 | 86 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 239 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2013 | 322 | 0.110 |
Why?
|
| Drug Synergism | 1 | 2013 | 171 | 0.110 |
Why?
|
| Drug Carriers | 1 | 2013 | 121 | 0.110 |
Why?
|
| Reference Standards | 2 | 2013 | 52 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 134 | 0.110 |
Why?
|
| Radioimmunoassay | 1 | 2012 | 66 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2013 | 147 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 413 | 0.110 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 75 | 0.110 |
Why?
|
| Cotinine | 1 | 2012 | 40 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2015 | 727 | 0.110 |
Why?
|
| Ethanol | 1 | 2013 | 188 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 292 | 0.100 |
Why?
|
| Models, Animal | 1 | 2012 | 131 | 0.100 |
Why?
|
| Kinetics | 1 | 2013 | 650 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 180 | 0.100 |
Why?
|
| Metabolomics | 3 | 2017 | 76 | 0.100 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 8 | 0.100 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2010 | 12 | 0.100 |
Why?
|
| Lymphokines | 1 | 2010 | 11 | 0.100 |
Why?
|
| Biosynthetic Pathways | 1 | 2010 | 13 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 31 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 198 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 336 | 0.100 |
Why?
|
| Haplotypes | 1 | 2010 | 152 | 0.090 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2010 | 129 | 0.090 |
Why?
|
| Refrigeration | 1 | 2009 | 4 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1300 | 0.090 |
Why?
|
| Transfection | 1 | 2010 | 496 | 0.090 |
Why?
|
| Drug Storage | 1 | 2009 | 27 | 0.090 |
Why?
|
| Suspensions | 1 | 2009 | 42 | 0.090 |
Why?
|
| Binding Sites | 1 | 2010 | 597 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2020 | 467 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 859 | 0.080 |
Why?
|
| gamma-Tocopherol | 1 | 2008 | 18 | 0.080 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 94 | 0.080 |
Why?
|
| Smoking | 1 | 2014 | 903 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 1530 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2333 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1426 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2008 | 418 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2015 | 323 | 0.060 |
Why?
|
| Sulfides | 1 | 2023 | 58 | 0.060 |
Why?
|
| Methanol | 1 | 2023 | 18 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 649 | 0.060 |
Why?
|
| Swine | 1 | 2023 | 182 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 894 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2022 | 80 | 0.050 |
Why?
|
| Liposomes | 1 | 2022 | 107 | 0.050 |
Why?
|
| Glucuronates | 1 | 2021 | 6 | 0.050 |
Why?
|
| Sulfates | 1 | 2021 | 23 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2021 | 25 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2021 | 56 | 0.050 |
Why?
|
| Intestines | 1 | 2021 | 63 | 0.050 |
Why?
|
| Piperidines | 1 | 2021 | 76 | 0.050 |
Why?
|
| Feces | 1 | 2021 | 110 | 0.050 |
Why?
|
| Hydrazones | 1 | 2020 | 5 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 182 | 0.050 |
Why?
|
| Chemistry, Physical | 1 | 2020 | 44 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 61 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 255 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 207 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 178 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1007 | 0.040 |
Why?
|
| Hypoxanthine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Xanthine | 1 | 2017 | 3 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 4 | 0.040 |
Why?
|
| Kidney | 1 | 2020 | 322 | 0.040 |
Why?
|
| Caffeine | 1 | 2017 | 26 | 0.040 |
Why?
|
| Urea | 1 | 2017 | 42 | 0.040 |
Why?
|
| United States | 1 | 2006 | 3894 | 0.040 |
Why?
|
| Nuchal Cord | 1 | 2015 | 1 | 0.030 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 570 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2014 | 1802 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 52 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 94 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 11 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 580 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 91 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 79 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 142 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 132 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 128 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 143 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 16 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 118 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 298 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 114 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2014 | 36 | 0.030 |
Why?
|
| Texas | 1 | 2015 | 299 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2013 | 25 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 58 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 242 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2013 | 32 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 287 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 206 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 317 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 150 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 707 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 176 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2014 | 1422 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 484 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 653 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 1023 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2013 | 301 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 1961 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 600 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4012 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 5035 | 0.020 |
Why?
|